BAC launches CaptureSelect technology for protein depletion from serum

BAC, the leading provider of antibody-based affinity purification technologies, announces the launch of CaptureSelect® HumanPlasma14 for highly specific, reproducible depletion of the 14 most abundant proteins from human blood plasma or serum. HumanPlasma14 is designed for single-step, single-use depletion of more than 99% of the abundant proteins. The resulting sample can then be used for further downstream applications including gel electrophoresis and mass spectrometry.

“Being able to support a loading capacity of 20-30 ul/ml means that there is less sample dilution and we experience better recovery and reproducibility compared to competitive products.”

HumanPlasma14 is the first product from BAC's CaptureSelect Proteomics Toolbox, which consists of a mixture of CaptureSelect ligands. CaptureSelect ligands are single-domain monospecific antibodies uniquely immobilized on high-capacity agarose-based beads, which have been proven in laboratory and large scale industrial applications and can be custom-combined for specific protein depletion needs. The slurry can be pre-packed into columns or used in custom-made formats.

"The single-use format of HumanPlasma14 avoids the common problems associated with column recycling, such as clogging, bead regeneration and potential contamination of precious samples", noted Prof. Marina Hincapie of Northeastern University. "Being able to support a loading capacity of 20-30 ul/ml means that there is less sample dilution and we experience better recovery and reproducibility compared to competitive products."

Laurens Sierkstra, CEO of BAC said: "HumanPlasma14 is the first product from our Proteomics Toolbox that utilises the unique properties of CaptureSelect technology. By producing highly specific ligands, we are extending our product range to include affordable solutions for protein depletion. Researchers will for the first time benefit from a single-use product that delivers consistent and reproducible results."

Source:

:  BAC

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
You might also like... ×
Phase I clinical trial of two Cuban recombinant protein COVID-19 vaccines